Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma.
Mitoxantrone was administered to 12 patients with advanced or recurrent endometrial carcinoma of whom only 1 had received prior chemotherapy (chlorambucil). The drug was given every 21 days, the initial dose of either 12 mg/m1 or 14 mg/m1 being decided by the patient's age, timing of prior radiotherapy, tolerance of prior chemotherapy and baseline haematological parameters. One partial response was observed in the 11 patients evaluable for assessment of response. Mitoxantrone was well tolerated with the major toxicity being myelosuppression, particularly granulocytopenia. With the observed response rate of 9%, we conclude that mitoxantrone does not have significant activity in endometrial carcinoma.
Boadle
D J
DJ
St Vincent's Hospital, Darlinghurst.
Tattersall
M H
MH
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D008942:Mitoxantrone